Clinical Validation of a Novel Software Tool to Guide the Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases

被引：0
|
作者：
Hoffert, Yannick [1 ]
Wang, Zhigang [1 ]
Fumery, Mathurin [2 ,3 ]
Nachury, Maria [4 ]
Bazoge, Maeva [5 ]
Buisson, Anthony [5 ]
Dreesen, Erwin [1 ]
机构：
[1] Katholieke Univ Leuven, Leuven, Vlaams Brabant, Belgium
[2] Picardie Jules Verne Univ, CHU Amiens, Amiens, Picardie, France
[3] Picardie Jules Verne Univ, Peritox, Amiens, Picardie, France
[4] Lille Univ & Hosp, Lille, Nord Pas De Cal, France
[5] Univ Clermont Auvergne, CHU Clemront Ferrand, Clermont Ferrand, Auvergne, France
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001034524.01104.8d
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1289
引用
收藏
页码：S921 / S922
页数：2
相关论文
共 50 条
  • [21] ONE-YEAR CLINICAL OUTCOMES OF SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON MAINTENANCE OF INTRAVENOUS INFLIXIMAB THERAPY WITH OR WITHOUT REMISSION: A MULTI-CENTER COHORT STUDY
    Bae, June Hwa
    Park, Jung-Bin
    Baek, Ji Eun
    Lee, Yoo Jin
    Kim, Kyeong Ok
    Kim, Eun Soo
    Jo, Hyeong Ho
    Hong, Seung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Ye, Byong Duk
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Kim, Eun Young
    Hwang, Sung Wook
    GASTROENTEROLOGY, 2024, 166 (05) : S1131 - S1131
  • [22] From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
    Verma, Ajay M.
    Patel, Anusha
    Subramanian, Sreedhar
    Smith, Philip J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 88 - 89
  • [23] Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
    Buisson, A.
    Nachury, M.
    Bazoge, M.
    Yzet, C.
    Wils, P.
    Dodel, M.
    Coban, D.
    Pereira, B.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1364 - I1364
  • [24] Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
    Parisio, Laura
    Settanni, Carlo Romano
    Varca, Simone
    Laterza, Lucrezia
    Lopetuso, Loris Riccardo
    Napolitano, Daniele
    Schiavoni, Elisa
    Turchini, Laura
    Fanali, Caterina
    Alfieri, Norma
    Pizzoferrato, Marco
    Papa, Alfredo
    Pafundi, Pia Clara
    Armuzzi, Alessandro
    Gasbarrini, Antonio
    Pugliese, Daniela
    Scaldaferri, Franco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (04) : 452 - 459
  • [25] Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
    Carbery, Isabel
    Burdge, Gemma
    Clark, Tanya
    Broglio, Giacomo
    Greer, Dan
    Alakkari, Alaa
    Selinger, Christian Philipp
    BMJ OPEN GASTROENTEROLOGY, 2023, 10 (01):
  • [26] Effect on direct and indirect costs of switching Inflammatory Bowel Disease patients from intravenous to subcutaneous infliximab (CT-P13)
    Carbery, I.
    Broglio, G.
    Clark, T.
    Greer, D.
    Alakkari, A.
    Selinger, C. P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 861 - 861
  • [27] Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases
    Outtier, An
    Ferrante, Marc
    DIGESTIVE DISEASES AND SCIENCES, 2025, 70 (01) : 17 - 18
  • [28] Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected
    Tursi, Antonio
    Mocci, Giammarco
    Elisei, Walter
    Savarino, Edoardo
    Maconi, Giovanni
    Scaldaferri, Franco
    Papa, Alfredo
    MINERVA GASTROENTEROLOGY, 2024,
  • [29] Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
    Smith, P. J.
    Storey, D.
    Gregg, B.
    Critchley, L.
    Stenson, J.
    Kneebone, A.
    Rimmer, T.
    Burke, S.
    Hussain, S.
    Teoh, W. Y.
    Vazeille, S.
    Serna, S.
    Bond, A.
    Steel, A.
    Dibb, M.
    Collins, P.
    Derbyshire, E.
    Bodger, K.
    Probert, C.
    Verma, A.
    Subramanian, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S480 - S481
  • [30] Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
    Gros, B.
    Mancenido Marcos, N.
    Guardiola, J.
    Alonso Abreu, I.
    Rodriguez Lago, I.
    Alvarado, R.
    Ponferrada, A.
    Orobitg Bernades, J.
    Arguelles-Arias, F.
    Mesonero, F.
    Guerra, I.
    Canete, F.
    Madero, L.
    Borras, P.
    Rodriguez, G. E.
    Iborra, M.
    Castro, J.
    Caballero Mateos, A.
    Barreiro-de Acosta, M.
    Huguet Malaves, J. M.
    Brunet-Mas, E.
    Lopez Romero-Salazar, F.
    Caballol, B.
    Zabana, Y.
    Suria Bolufer, C.
    Soto, P.
    Castro, B.
    Marin, S.
    Porto-Silva, S.
    Benitez, J. M.
    Gutierrez, A.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1784 - I1786
12345